Nuvectra Completes 3,000 U.S. Algovita SCS Implantations
Nuvectra (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S. As quoted in the press release: The Algovita system utilizes patent-protected stretchable lead technology with a robust internal pulse generator to deliver four stimulation modes to patients for …
Nuvectra (NASDAQ:NVTR), a neurostimulation medical device company, announced today that the Company’s Algovita Spinal Cord Stimulation (SCS) system has been implanted in over 3,000 patients in the U.S.
As quoted in the press release:
The Algovita system utilizes patent-protected stretchable lead technology with a robust internal pulse generator to deliver four stimulation modes to patients for non-pharmaceutical relief of pain.
Scott Drees, Chief Executive Officer, commented, “We are excited to achieve another significant U.S. commercial milestone with the 3,000th implantation of the Algovita system. Our growth continues to accelerate with an expanded sales force and supportive physician and patient feedback on the efficacy of the system. We look forward to advancing our growth strategy and driving market share gains.”